What is claimed is:

1. A compound of formula I

wherein

5

20

30

R1 is

hydrogen atom or $-(C_1-C_6)$ -alkyl,

R2 is

-(C₁-C₆)-alkyl that is substituted, once, twice or three times, by

 $-C(O)-O-R^{8}$,

 $-(C_1-C_6)-alkyl-O-R^8,$

–(C_6 - C_{14})-aryl that is substituted, once, twice or three times, independently of each other, by R^{11} or

Het that is a saturated or unsaturated monocyclic or bicyclic, 3- to 10membered heterocyclic ring system which contains 1, 2 or 3
identical or different ring heteroatoms selected from the group
consisting of nitrogen, oxygen and sulfur and is unsubstituted or
substituted, once or more than once, by R¹³,

R³, R⁴, R⁵, R⁶ and R⁷ are identical or different and are, independently of each other,

25 hydrogen

halogen,

- -(C₁-C₆)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen,
- -O-(C₁-C₆)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, or

 $-S-(C_1-C_6)$ -alkyl,

```
R<sup>8</sup> is
                  hydrogen atom, or
                  -(C_1-C_6)-alkyl,
 5
        R<sup>11</sup> is
                  -(C_2-C_6)-alkyl-C(O)-O-R^8,
                  -O-(C_1-C_6)-alkyl-C(O)-O-R<sup>8</sup>,
                  -NR^{14}R^{15},
                  -(CH_2)_k-NR^9R^{10},
10
                  -O-(C_2-C_6)-alkyl-NR<sup>9</sup>R<sup>10</sup>, or
                  -NR<sup>8</sup>-C(O)-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, in which alkyl is unsubstituted or substituted, once,
                            twice or three times, by R<sup>12</sup>,
        R<sup>9</sup> and R<sup>10</sup> are identical or different and are, independently of each other,
15
                  hydrogen atom, or
                  -(C_1-C_6)-alkyl, or
                  taken together with the nitrogen atom to which they are attached form a 5-, 6- or
                  7-membered saturated azaheterocyclyl ring wherein one or two further carbon
20
                  atoms thereof are optionally replaced by a heteroatom that is an oxygen, sulfur or
                  nitrogen atom, and wherein the nitrogen atom is optionally unsubstituted or
                  substituted by (C<sub>1</sub>-C<sub>6</sub>)-alkyl,
        k is
25
                            2, 3, 4 or 5,
        R<sup>12</sup> is
                  halogen,
                  cyano,
30
                  nitro,
                  hydroxyl,
                  amino,
                  -C(O)-O-(C_1-C_6)-alkyl, or
                  -C(O)-OH,
```

35

35

R¹³ is halogen, cyano, nitro, 5 hydroxyl, amino, $-C(O)-O-(C_1-C_6)$ -alkyl, -C(O)-OH, $-(C_1-C_6)$ -alkyl that is unsubstituted or substituted, once, twice or three times, by 10 halogen, -O-(C₁-C₆)-alkyl, where alkyl is unsubstituted or substituted, once, twice or three times, by halogen, pyridyl, or phenyl that is unsubstituted or substituted, once or more than once and 15 independently of each other, by a radical from the series halogen, (C₁-C₆)alkoxy and (C₁-C₆)-alkyl, and R¹⁴ and R¹⁵ together with the nitrogen atom to which they are attached form a 5-, 6- or 7-membered saturated azaheterocyclyl ring wherein one or two further 20 carbon atoms thereof are optionally replaced by a heteroatom that is oxygen, sulfur or nitrogen, and wherein each nitrogen atom thereof is optionally independently unsubstituted or substituted by (C₁-C₆)-alkyl, or stereoisomer thereof, a mixture of stereoisomers thereof in any ratio, or physiologically 25 tolerable salt thereof. 2. The compound according to claim 1, wherein R² is $-(C_1-C_4)$ -alkyl, where alkyl is substituted, once, twice or three times, by -C(O)-O-R⁸, 30 $-(C_1-C_4)$ -alkyl-O-R⁸, phenyl that is substituted, once, twice or three times, independently of each other, by R¹¹, or Het that is azepine, azetidine, aziridine, benzimidazole, benzo[1,4]dioxin,

1,3-benzodioxole, benzofuran, 4H-benzo[1,4]oxazine,

35

benzoxazole, benzothiazole, benzothiophene, quinazoline, quinoline, quinoxaline, chroman, cinnoline, oxirane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, 1,4-dioxin, dioxole, furan, imidazole, indazole, indole, isoquinoline, isochroman, 5 isoindole, isoxazole, isothiazole, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, phthalazine, piperidine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyridoimidazole, pyridopyridine, pyridopyrimidine, pyrrol, tetrazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, thiazole, thiophene, thiopyran, 10 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4triazole, and Het is unsubstituted or substituted, once, twice or three times, independently of each other, by R¹³ R³, R⁴, R⁵, R⁶ and R⁷ are identical or different and are 15 hydrogen atom, halogen, $-(C_1-C_6)$ -alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, or -O-(C₁-C₆)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or 20 three times, by halogen, R8 is hydrogen atom, or $-(C_1-C_4)$ -alkyl, 25 R11 is $-(C_2-C_4)$ -alkyl-C(O)-O-R⁸, $-O-(C_1-C_4)$ -alkyl-C(O)-O-R⁸, -N R¹⁴R¹⁵, wherein R¹⁴ and R¹⁵ taken together with the nitrogen atom to which 30 they are attached form imidazolidine, isothiazolidine, isoxazolidine, morpholine, piperazine, piperidine, pyrazine, pyrazolidine, pyrrolidine, tetrazine or thiomorpholine, and wherein each nitrogen atom thereof is optionally independently unsubstituted or substituted by (C₁-C₄)-alkyl, $-(CH_2)_k-N R^9 R^{10}$

 $-O-(C_2-C_4)$ -alkyl-NR⁹R¹⁰, or

-NH-C(O)-(C_1 - C_4)-alkyl, wherein the alkyl is unsubstituted or substituted, once, twice or three times, by R^{12} ,

R⁹ and R¹⁰ are identical or different and are, independently of each other,

5 hydrogen atom, or

 $-(C_1-C_4)$ -alkyl, or

taken together with the nitrogen atom to which they are attached form imidazolidine, isothiazolidine, isoxazolidine, morpholine, piperazine, piperidine, pyrazine, pyrazolidine, pyrrolidine, tetrazine or thiomorpholine, and wherein the nitrogen atom is optionally unsubstituted or substituted by $-(C_1-C_4)$ -alkyl,

k is

2, 3 or 4, and

15 R¹³ is

10

halogen,

amino,

 $-C(O)-O-(C_1-C_4)$ -alkyl,

-C(O)-OH,

- 20 –(C₁-C₆)-alkyl that is unsubstituted or substituted, once, twice or three times, by halogen,
 - -O-(C₁-C₆)-alkyl, wherein the alkyl is unsubstituted or substituted, once, twice or three times, by halogen,

pyridyl, or

- phenyl that is unsubstituted or substituted, once or more than once and independently of each other, by a radical from the series halogen, -(C₁-C₄)-alkoxy and -(C₁-C₄)-alkyl.
 - 3. The compound according to claim 1, wherein

30 R¹ is

hydrogen,

R² is

-(C₁-C₂)-alkyl that is substituted, once, twice or three times, by

```
phenyl that is substituted, once, twice or three times, independently of
                                      each other, by R11, or
                            Het that is furan, imidazole, isothiazole, isoxazole, oxazole, pyrazole,
                                      pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene,
 5
                                      1,2,3-triazole or 1,2,4-triazole, and Het is unsubstituted or
                                      substituted, once, twice or three times, independently of each
                                      other, by R<sup>13</sup>,
        R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are identical or different and are, independently of each other,
10
                  hydrogen,
                  halogen,
                  methyl,
                  trifluoromethyl,
                  methoxy, or
15
                  trifluoromethoxy,
        R<sup>8</sup> is
                  hydrogen atom, or
                  -(C_1-C_4)-alkyl,
20
        R11 is
                  -(C_2-C_4)-alkyl-C(O)-O-R<sup>8</sup>,
                  -O-(C_1-C_4)-alkyl-C(O)-O-R<sup>8</sup>.
                  -N R<sup>14</sup>R<sup>15</sup>, wherein R<sup>14</sup> and R<sup>15</sup> taken together with the nitrogen atom to which
                            they are attached form imidazolidine, isothiazolidine, isoxazolidine,
25
                            morpholine, piperazine, piperidine, pyrazine, pyrazolidine, pyrrolidine,
                            tetrazine or thiomorpholine, and wherein each nitrogen atom thereof is
                            optionally independently unsubstituted or substituted by (C<sub>1</sub>-C<sub>4</sub>)-alkyl,
                  -(CH_2)_k-NR^9R^{10}
                  -O-(C_2-C_4)-alkyl-NR<sup>9</sup>R<sup>10</sup>, or
30
                  -NH-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or substituted, once,
                            twice or three times, by R<sup>12</sup>,
        R<sup>9</sup> and R<sup>10</sup> are identical or different and are, independently of each other,
35
                  hydrogen atom, or
```

- (C_1-C_4) -alkyl, or

taken together with the nitrogen atom to which they are attached form imidazolidine, isothiazolidine, isoxazolidine, morpholine, piperazine, piperidine, pyrazine, pyrazolidine, pyrrolidine, tetrazine or thiomorpholine, and wherein the nitrogen atom is optionally unsubstituted or substituted by $-(C_1-C_4)$ -alkyl,

k is

5

2, 3 or 4,

10 R¹² is

halogen,

 $-C(O)-O-(C_1-C_4)$ -alkyl, or

-C(O)-OH, and

15 R^{13} is

halogen,

amino,

 $-C(O)-O-(C_1-C_4)$ -alkyl,

-C(O)-OH,

- 20 –(C₁-C₄)-alkyl that is unsubstituted or substituted, once, twice or three times, by halogen,
 - -O-(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or substituted, once, twice or three times, by halogen,

pyridyl, or

- 25 phenyl that is unsubstituted or substituted, once or more than once and independently of each other, by a radical from the series halogen, $-(C_1-C_4)$ -alkoxy and $-(C_1-C_4)$ -alkyl.
- 4. A method for the prophylaxis or therapy of a patient having or subject to a disease whose course involves a detrimental increase in the activity of matrix metalloproteinase 13, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.
- 5. A method for the prophylaxis or therapy of a patient having or subject to a disease whose course involves a detrimental increase in the activity of matrix

metalloproteinase 13, comprising administering to said patient a therapeutically effective amount of a compound according to claim 2.

- 6. A method for the prophylaxis or therapy of a patient having or subject to a disease whose course involves a detrimental increase in the activity of matrix metalloproteinase 13, comprising administering to said patient a therapeutically effective amount of a compound according to claim 3.
- 7. A process for preparing the compound of formula I according to claim 1,10 comprising
 - a) reacting a compound of formula II

15 wherein Y is

halogen, hydroxyl or C_1 - C_4 -alkoxy, or forms, together with the carbonyl group, an active ester or a mixed anhydride,

with a compound of formula IIIa

20

wherein R^1 and R^2 , have the meanings given in the compound of formula I, to form a compound of formula IVa

b) reacting the compound of formula IVa with a compound of formula IIIb

$$R^{4}$$
 R^{5}
 R^{6}
 R^{7}
 R^{7}
(IIIIb)

5

wherein R^3 , R^4 , R^5 , R^6 and R^7 have the meanings given in the compound of formula I, to form the compound of formula I.

- 10 8. A process for preparing the compound of formula I according to claim 1, comprising
 - a) reacting a compound of formula II

15

wherein Y is

halogen, hydroxyl or C_1 - C_4 -alkoxy, or forms, together with the carbonyl group, an active ester or a mixed anhydride, with a compound of formula IIIb

20

$$R^4$$
 R^3
 R^5
 R^6
 R^7
 R^7
(IIIb)

wherein R³, R⁴, R⁵, R⁶ and R⁷ have the meanings given in the compound of formula I,

5 to form a compound of formula IVb

10

15

b) reacting the compound of formula IVb with a compound of formula IIIa

wherein R^1 and R^2 , have the meanings given in the compound of formula I, to form the compound of formula I.

- 9. A pharmaceutical preparation comprising a pharmaceutically effective amount of at least one compound of formula I according to claim 1 and a pharmaceutically suitable and physiologically tolerated carrier.
- 20 10. A use of the compound according to claim 1 for the prophylaxis or therapy of a patient having or subject to a disease that involves a detrimental increase in the activity of matrix metalloproteinase 13, comprising administering to the patient a pharmaceutically effective amount of at least one compound of formula I.

11. The use according to claim 10 wherein the disease is a degenerative joint disease, or disease of the connective tissue, chronic disease of the locomotory apparatus or cancer disease such as breast cancer.